Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eledon Pharmaceuticals Inc (NQ: ELDN )

2.450 -0.120 (-4.67%)
Streaming Delayed Price Updated: 2:31 PM EST, Nov 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,643
Open 2.470
Bid (Size) 2.410 (2)
Ask (Size) 2.470 (1)
Prev. Close 2.570
Today's Range 2.420 - 2.470
52wk Range 2.270 - 5.296
Shares Outstanding 13,756,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via Globe NewsWire
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
Management to host conference call and webcast at 4:30 pm ET 
From Eledon Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
-48.53%
-48.53%
1 Month
+1.66%
+1.66%
3 Month
-36.86%
-36.86%
6 Month
-23.20%
-23.20%
1 Year
-51.49%
-51.49%

More News

Read More
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
From Eledon Pharmaceuticals, Inc.
Via Globe NewsWire
Eledon Pharma: Q2 Earnings Insights
Via Benzinga
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
From Eledon Pharmaceuticals, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Eledon Shares Climb After Securing FDA Nod For Mid-Stage Kidney Disease Study
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Eledon Pharmaceuticals Earnings: A Preview
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Via Benzinga
Eledon Secures FDA Clearance For Kidney Transplant Rejection Study
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Via Benzinga
Eledon Pharmaceuticals' Stock Gains As FDA Grants Orphan Drug Designation
Via Benzinga
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Eledon Pharma: Q1 Earnings Insights
Via Benzinga
Earnings Outlook For Eledon Pharmaceuticals
Via Benzinga
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Via Benzinga
88 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
Earnings Scheduled For March 24, 2022
Via Benzinga
A Preview Of Eledon Pharmaceuticals's Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.